Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GB:GSK)
LSE:GSK
GSK Stock Chart & Stats
Day’s Range― - ―
52-Week Range1,242.50p - 1,823.50p
Previous CloseN/A
Volume367.08K
Average Volume (3M)10.53M
Market Cap
£58.60B
Enterprise Value73.93B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)18.8
Beta0.72
Next Earnings
Jul 30, 2025EPS Estimate
43.2Next Dividend Ex-Date
May 15, 2025Dividend Yield4.21%
Share Statistics
EPS (TTM)0.77
Shares Outstanding4,109,731,400
10 Day Avg. Volume8,773,930
30 Day Avg. Volume10,525,169
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£1,533.08Price Target Upside5.84% Upside
Rating ConsensusHold
Number of Analyst Covering14
---
Bulls Say, Bears Say
Bulls Say
Product LaunchThe launch of Nucala for COPD has shown positive results in clinical trials, potentially providing an advantage over competing treatments.
Product PerformanceJemperli has a broad endometrial label and is the only PD1/L1 with significant overall survival in first-line treatment, offering opportunities for combination with other drugs.
Strategic ManagementGSK's strategic focus on navigating and mitigating tariffs is seen as a positive capability to manage external challenges.
Bears Say
Earnings GrowthGSK is projected to have the worst EPS growth rate in the sector between 2026 and 2029, with a decline of 5% as key franchises mature or decline.
Loss Of ExclusivityGSK's longer-term challenges with loss of exclusivity and growth issues lead to a reiterated underperform rating.
Research And DevelopmentHigher research and development expenses are expected to impact GSK's earnings per share negatively in the coming years.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.10% Insiders
11.11%
Mutual Funds
0.08% Other Institutional Investors
75.90% Public Companies and
Individual Investors
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest share price was 1242.50p and its highest was 1823.50p in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is £58.60B.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Jul 30, 2025 which is in 86 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Apr 30, 2025. The company reported 0.449p earnings per share for the quarter, beating the consensus estimate of 0.4p by 0.049p.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Annually dividend of 15.999p which represents an annual dividend yield of 4.21%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 43.2.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 4,109,731,400 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of 0.449p in its last earnings report, beating expectations of 0.4p. Following the earnings report the stock price went up 3.596%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GB:GSK
---
GlaxoSmithKline Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
£1,533.08 (5.84% Upside)
£1,533.08 (5.84% Upside)
Insider Transactions
Sold Shares
Worth £11.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.77%
12-Months-Change
Fundamentals
Return on Equity
22.52%
Trailing 12-Months
Asset Growth
3.75%
Trailing 12-Months
Company Description
GlaxoSmithKline
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
---
GSK Stock 12 Month Forecast
Average Price Target
1,533.08p
▲(5.84% Upside)
Technical Analysis
---